People with chronic lymphocytic leukemia (CLL) can have different genetic mutations that affect their prognosis and treatment outcomes. Specifically, mutations in the immunoglobulin heavy chain variable region (IGHV) gene play a significant role:

- Mutated IGHV: Often associated with a better outlook, more effective Show Full Answer

People with chronic lymphocytic leukemia (CLL) can have different genetic mutations that affect their prognosis and treatment outcomes. Specifically, mutations in the immunoglobulin heavy chain variable region (IGHV) gene play a significant role:

- Mutated IGHV: Often associated with a better outlook, more effective treatment, and longer survival rates. In one study, 82% of people with mutated IGHV were in complete remission after six years.
- Unmutated IGHV: Typically linked to a less favorable prognosis. In the same study, only 47% of people with unmutated IGHV were in complete remission after six years.

If you are unmutated, it means you might have a less favorable prognosis compared to those with mutated IGHV. However, it's important to discuss your specific case with your healthcare provider to understand your individual situation better.

 This AI-generated response comes from MyLeukemiaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Chronic Lymphocytic Leukemia Survival Rate and Outlook | MyLeukemiaTeam

Is Chronic Lymphocytic Leukemia (CLL) Hereditary? | MyLeukemiaTeam